Effects of Vaping on Post-operative Recurrence of Crohn's Disease
Launched by IRCCS OSPEDALE SAN RAFFAELE · Dec 11, 2024
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how vaping, or the use of electronic cigarettes, affects the recurrence of Crohn's disease after patients undergo surgery to remove part of their intestines. Researchers want to find out if vaping has a different impact on patients compared to those who smoke traditional tobacco cigarettes or do not smoke at all. Since tobacco smoke is known to worsen Crohn's disease outcomes, understanding the effects of vaping is important for doctors in deciding how to treat patients after surgery.
To participate in the study, you need to be an adult with a confirmed diagnosis of Crohn's disease who has had surgery to remove a part of your intestines. Your smoking habits must be clearly documented, whether you smoke traditional cigarettes, vape, or don’t smoke at all. Participants will be monitored for up to 12 months after their surgery to see how their Crohn's disease responds. This research aims to provide valuable information that could help guide treatment decisions for patients with Crohn's disease who use e-cigarettes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (age ≥18) patients with an established diagnosis of Crohn's disease.- Patients who underwent surgical resections of a tract of intestine accessible through endoscopy.
- • Patients who underwent ileo-colic resections due to Crohn's disease or its complications (stricture or fistula) irrespective of the type of anastomosis (side-to-side L-L, , end-to-end T-T, end-to-side T-L, Kono S, iso or antiperistaltic)
- • Patients whose smoking habit (or nonsmoking habit) is clearly reported in the medical records
- • Data will be collected from January 2000 to August 2024.
- Exclusion Criteria:
- • Patients who underwent surgical operations different from intestinal resections (i.e. stricturoplasty raffias, dilation, bypass etc)
- • Patients who underwent Intestinal resections for indications other than Crohn's disease (inflammatory, stricturing or fistulizing) such as: cancer, trauma, etc
- • Patients who for any reason did not undergo endoscopic reassessment of the anastomosis within 12 months from surgery
- • Unconfirmed diagnosis of Crohn's disease
- • Patients whose smoking habits could not be determined
- • Patients with mixed smoking habits, defined as smoking at the same time tobacco cigarettes and e-cigarettes or who have changed type of smoking product (from tobacco to vaping or vice versa) after the intestinal resection and before the endoscopic reassessment
About Irccs Ospedale San Raffaele
IRCCS Ospedale San Raffaele is a leading research hospital and clinical trial sponsor based in Milan, Italy, renowned for its commitment to advancing medical knowledge and improving patient care through innovative research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with cutting-edge scientific research, focusing on a wide range of therapeutic areas including oncology, neurology, and cardiovascular diseases. The institution is dedicated to conducting high-quality clinical trials that adhere to rigorous ethical standards, fostering collaboration among multidisciplinary teams to translate scientific discoveries into effective treatments for patients. Through its robust infrastructure and expertise, IRCCS Ospedale San Raffaele plays a pivotal role in shaping the future of healthcare both nationally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, Michigan, Italy
Patients applied
Trial Officials
Tommaso Lo Parigi, MD
Principal Investigator
IRCCS Ospedale San Raffaele
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported